The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Survival benefits of second-line chemotherapy in metastatic castrate-resistant prostate cancer (CRPC) in a southeastern oncology community practice.
James W. Gilmore
No relevant relationships to disclose
Sally Haislip
No relevant relationships to disclose
Stephen Szabo
Employment or Leadership Position - Georgia Cancer Specialists
Consultant or Advisory Role - Amgen
Sean D Sullivan
Consultant or Advisory Role - Bayer
Scott David Ramsey
Consultant or Advisory Role - Bayer
Charles Kreilick
Employment or Leadership Position - Bayer
Susan H Foltz Boklage
Employment or Leadership Position - Bayer
Syam Sarma
Consultant or Advisory Role - Bayer
Carl V Asche
Consultant or Advisory Role - Bayer
Kenneth M. Shermock
Consultant or Advisory Role - Bayer
Kai Sun
No relevant relationships to disclose
Satish Valluri
Employment or Leadership Position - Bayer
Brian S. Seal
Employment or Leadership Position - Bayer
Stock Ownership - Bayer